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Although equine diphtheria antitoxin may be an effective therapy for human diphtheria, its use often induces
serum sickness. We describe here a strategy for developing an alternative treatment based on the human
diphtheria toxin (DT) receptor/heparin-binding epidermal growth factor-like growth factor (HB-EGF) precur-
sor. Recombinant mature human HB-EGF acts as a soluble receptor analog, binding radioiodinated DT and
preventing its binding to the cellular DT receptor/HB-EGF precursor. However, the possibility existed that
radioiodinated DT-HB-EGF complexes associate with cells due to the binding of the heparin-binding domain
of recombinant HB-EGF to cell surface heparan sulfate proteoglycans. This possibility was confirmed by
performing DT binding studies in the presence of heparin. A recombinant truncated HB-EGF (residues 106 to
149), which lacks most of the heparin-binding domain, showed an essentially heparin-independent binding of
radioiodinated DT to cells. Furthermore, it was a more effective inhibitor of DT binding than was recombinant
mature HB-EGF. Since mature HB-EGF is a known ligand for the EGF receptor and is thus highly mitogenic
(tumorigenic), we then changed amino acid residues in the EGF-like domain of the recombinant truncated
HB-EGF and demonstrated that this DT receptor analog (I117A/L148A) displayed a low mitogenic effect. The
truncated (I117A/L148A) HB-EGF protein retained high DT binding affinity, as confirmed by using surface
plasmon resonance. Our results suggest that the truncated (I117A/L148A) HB-EGF protein could be an
effective, safe antidote for human diphtheria.
Although several years ago it appeared that diphtheria was
no longer a major public health threat, the recent resurgence
of diphtheria in the New Independent States of the former
Soviet Union (8, 9), Ecuador (35), Thailand (7), Algeria, and
elsewhere (21) suggests that this old menace remains a signif-
icant global health problem. Historically, diphtheria patients
have been treated with equine antitoxin, which neutralizes
unbound toxin; however, surviving patients have often devel-
oped serum sickness, an immune complex-type disease. Thus,
a better treatment for diphtheria patients is needed. Diphthe-
ria toxin (DT) is a Corynebacterium diphtheriae exotoxin that
inhibits protein synthesis of toxin-sensitive eukaryotic cells. DT
is translated as a single polypeptide of 535 amino acid residues
(Mr, 58,342). Partial proteolysis yields a disulfide-linked poly-
peptide composed of two fragments: the enzymatic A fragment
(Mr, 21,167) and the receptor-binding/translocation-mediating
B fragment (Mr, 37,195) (13, 15, 20, 31, 36).
DT binds to cell surface DT receptors and is internalized by
receptor-mediated endocytosis (18). Upon subsequent acidifi-
cation of the endosome, the A fragment is translocated into the
cytosol, where the toxin inhibits protein synthesis by ADP
ribosylation of elongation factor 2. Although all elongation
factor 2s in mammalian species are sensitive to DT (30), only
those cells displaying a specific DT receptor are sensitive to the
toxin (32).
One laboratory previously cloned from highly toxin-sensitive
monkey Vero cells the cDNA encoding a DT receptor that
conferred DT sensitivity to normally toxin-resistant mouse L-
M(TK) cells (34). The predicted amino acid sequence of the
DT receptor was found to be identical to that of the cell
surface-expressed heparin-binding epidermal growth factor-
like growth factor (HB-EGF) precursor (proHB-EGF) (23).
HB-EGF is a member of the EGF growth factor family, which
includes EGF (14), transforming growth factor  (TGF-)
(17), epiregulin (44), amphiregulin (AR) (40), betacellulin
(BTC) (39), and heregulins (25). Although these members
were first purified and identified as secreted mature peptides,
subsequent sequencing of their cDNAs revealed that all are
derived from membrane-bound precursors that are proteolyti-
cally cleaved from the cellular membrane. Although proHB-
EGF is cleaved and released as soluble mature HB-EGF (22),
a significant amount of proHB-EGF remains on the cell sur-
face and functions as a juxtacrine growth factor (24) and as a
DT receptor (27, 34). Soluble mature HB-EGF binds to the
EGF receptor and is a more potent mitogen for smooth muscle
cells than is EGF (23). In addition to the monkey (Mk) proHB-
EGF, the proHB-EGF cDNAs of human (Hu) (23), mouse (1),
rat (1, 42), and hamster (11) have been cloned. The predicted
structure of proHB-EGFs (Fig. 1A) includes a signal sequence
(residues 1 to 23), a pro region (residues 24 to 62), the mature
growth factor (residues 63 to 148), a juxtamembrane domain
(residues 149 to 159), a transmembrane domain (residues 160
to 184), and a carboxyl-terminal cytoplasmic domain (residues
185 to 208). HB-EGF, like all members of the EGF growth
factor family, contains an EGF-like domain, which has 6 con-
served cysteine residues that form three disulfide bonds (linked
C1OC3, C2OC4, and C5OC6 [Fig. 1B]). This EGF-like motif
is important for tertiary structure stabilization, EGF receptor
binding, and DT binding.
The binding of growth factors to cell surfaces and extracel-
lular matrices is often mediated by proteoglycans. Many
growth factors are known to interact with heparin and heparan
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FIG. 1. (A) Comparison of Mk (upper line) (34) and human (Hu) (lower line) (23) HB-EGF precursors. Identical amino acid residues are
denoted by dashes, and differing residues are denoted by their single-letter amino acid code. The signal sequence, mature growth factor domain,
and the transmembrane domain are indicated by shaded boxes and are based on the designations of Abraham et al. (1). Three stretches of basic
amino acids in the HB domain (93KRKKKGK, 103KKR, and 110RKYK) are indicated by the three black boxes. Ile117 and Leu148 are indicated by
the residue number. The beginning (residue 106) and the end (residue 148) of the EGF-like domain are denoted by asterisks. (B) EGF-like
domains sequence comparison of Hu HB-EGF with the other members of the Hu EGF family. EPR, epiregulin. All sequences were obtained from
GenBank. The numbers at the top refer to the position of the residues in the Mk HB-EGF precursor, including the signal sequence shown in panel
A (34). The shaded boxes indicate residues that are identical to those in Mk HB-EGF. The characteristic six conserved cysteine residues, which
form three disulfide bonds (linked C1OC3, C2OC4, and C5OC6), are marked with arrows. Critical residues (I133, H135, and E141) for DT binding
are marked with asterisks. The residues noted for Hu EGF correspond to residues 4 to 47 of its mature form, the residues noted for Hu TGF-
correspond to residues 6 to 48 of its mature form, the residues noted for Hu epiregulin correspond to residues 4 to 46 of its mature form, the
residues noted for Hu BTC correspond to residues 36 to 78 of its mature form, and the residues noted for Hu AR correspond to residues 44 to
84 of its mature form (41).
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sulfate proteoglycans (HSPGs); these growth factors include
HB-EGF, AR, BTC, platelet-derived growth factor, acidic fi-
broblast growth factor, basic fibroblast growth factor, vascular
endothelial growth factor, and granulocyte-macrophage colo-
ny-stimulating factor (16). Using a combination of site-directed
mutagenesis and synthetic peptide studies, the sequences
within HB-EGF that mediate its interaction with heparin were
located in the middle of the protein (residues 93 to 113 in the
precursor sequence [Fig. 1A]) (3, 43). Three stretches of basic
amino acids within this region (93KRKKKGK, 103KKR, and
110RKYK [Fig. 1A]) have been shown to play a critical role in
HB; interestingly, the third region is within the EGF-like do-
main of HB-EGF.
The discovery that the DT receptor is a growth factor pre-
cursor raises the possibility that a soluble receptor analog
might be used therapeutically to block the binding of toxin to
the membrane DT receptor. A laboratory earlier reported that
recombinant mature Hu HB-EGF (residues 63 to 148), which
is identical to the mature Mk HB-EGF (except that Asn87 of
human is replaced with Ser87 in the monkey [Fig. 1A]), strongly
inhibits the binding of radiolabeled DT to toxin receptor-bear-
ing cells (26). This result suggested that it would be theoreti-
cally possible to treat diphtheria patients with mature HB-
EGF, which is a natural growth factor. This approach would
have significant advantages over the presently used equine
antitoxin, which often causes serum sickness, an immune com-
plex-type disease. However, mature HB-EGF might produce
side effects due to its growth factor activity.
We present here a rationale for the design of such a modern
antidote for diphtherial disease. The newly designed recombi-
nant protein is a more effective inhibitor of DT binding and is
significantly less mitogenic (tumorigenic) than recombinant
mature HB-EGF.
MATERIALS AND METHODS
Materials. The plasmid vector pcDNA3 and the Escherichia coli host strains
TOP10F and DH5 were purchased from Invitrogen. The protein expression
vector pET21a, the protein expression E. coli host strain BL21(DE3), and the T7
tag purification kit were obtained from Novagen. The recombinant mature Hu
HB-EGF and AR were from R&D Systems. Waymouth’s medium powder was
from Life Technologies, Inc. Insulin-transferrin-selenium-X culture supplement
was from Collaborative Biomedical Products (Bedford, Mass.). The BALB/c/3T3
cell line (ATCC CCL-163) was from the American Type Culture Collection.
[125I]NaI (IMS 30; 13 to 17 mCi/g), L-[4,5-3H]leucine (60 Ci/mmol), and [meth-
yl-3H]thymidine (2 Ci/mmol) were obtained from Amersham. Partially purified
DT was purchased from Connaught Laboratories (Willowdale, Ontario, Canada)
and was purified further by anion-exchange chromatography according to pub-
lished methods (37). The BIAcore 2000 system and CM5 sensor chips were
obtained from Pharmacia. All other reagents were as previously described (2, 4,
10, 12).
Plasmid construction. The plasmid pcDNA3 is a mammalian expression vec-
tor that allows growth in the presence of Geneticin. The wild-type Mk proHB-
EGF cDNA (34) was subcloned into the expression vector pcDNA3 using the
HindIII and XbaI restriction sites as described previously (26). The resulting
plasmid was named pMkHB-EGF. To create pMkHB-EGF/F115A, pMkHB-
EGF/I117A, pMkHB-EGF/Y138A, pMkHB-EGF/L148A, pMkHB-EGF/
F115A/L148A, pMkHB-EGF/I117A/L148A, and pMkHB-EGF/Y138A/L148A,
site-directed mutagenesis was performed using the Quikchange kit (from Strat-
agene) as described previously (10). Oligonucleotides were synthesized by
GIBCO/BRL and were used as primers to generate and to sequence the mutants
used in this study. The mutated sequences of the proHB-EGF cDNAs were
confirmed by automated sequencing using the ABI PRISM dye terminator cycle-
sequencing ready-reaction kit with the ABI Prism 377 DNA Sequencer at the
sequencing facilities of our institution. The desired mutants of proHB-EGF
cDNA were recloned into pcDNA3 at the HindIII and XbaI restriction sites.
The pET21a plasmid was used for protein expression in E. coli. The coding
regions (residues 63 to 149 for wild-type-sized recombinant HB-EGF or residues
106 to 149 for those proteins with a deletion of the HB domain) were amplified
by PCR with pMkHB-EGF, pMkHB-EGF/I117A/L148A, or pMkHB-EGF/
Y138A/L148A templates and were cloned into pET21a using the BamHI and
HindIII sites, resulting in pET21a/WT, pET21a/HB, pET21a/HB/I117A/
L148A, and pET21a/HB/Y138A/L148A plasmids. The mutated sequences of
HB-EGF were confirmed by automated sequencing as described above.
Transfection. Electroporation was used to transfect plasmid DNA into LCD9
cells using the BTX ECM 600 System as described previously (10) with the
following modifications. The LCD9 cell line is DT resistant and hygromycin
resistant; the construction and biochemical characterization of this cell line are
described in detail elsewhere (5). LCD9 cells were transfected with the wild-type
DT receptor/Mk proHB-EGF plasmid pMkHB-EGF (10) and with the seven DT
receptor mutant plasmids (pMkHB-EGF/F115A, pMkHB-EGF/I117A, pMkHB-
EGF/Y138A, pMkHB-EGF/L148A, pMkHB-EGF/F115A/L148A, pMkHB-
EGF/I117A/L148A, and pMkHB-EGF/Y138A/L148A), and cloned cell lines sta-
bly expressing the wild-type or mutant DT receptor were obtained. The cell lines
were screened for the presence of cell surface proHB-EGF by the abbreviated
cytotoxicity assay.
Abbreviated cytotoxicity assay. We used the previously described abbreviated
cytotoxicity assay (2, 10) to observe the inhibition of protein synthesis by DT.
Cells were tested with one concentration of DT (1 g/ml) and no DT as a
negative control. Protein synthesis inhibition was measured by [3H]leucine in-
corporation into acid-precipitable radioactivity as described previously (19, 38).
Each assay included the LCD9/Mk HB-EGF cell line described previously (10)
as a positive control and the LCD9 cell line as a negative control. Cell lines in
which protein synthesis was inhibited by 50% or more at 1 g of DT/ml were
considered to be DT sensitive. All individual DT-sensitive cell lines were sub-
cloned to obtain pure stable cell populations as described previously (10); the
presence of cell surface Mk CD9 was verified by a quantitative whole-cell en-
zyme-linked immunosorbent assay as described previously (10) and was further
analyzed by a radiolabeled DT binding assay described below.
Radiolabeled DT binding assay. The ability of wild-type and mutant DT
receptor-expressing cell lines to bind radioiodinated DT was examined as pre-
viously described (5, 34) with modifications. For this assay, 125I-labeled DT (0.4
to 400 nM) was added to the cell monolayers with or without a 100-fold-excess
unlabeled DT. Cell-associated radioactivity was determined employing a Tm
Analytical Gamma Trac 1290 g counting system. Specific binding was determined
as the difference between the total cell-associated radioactivity without excess
unlabeled DT and the cell-associated radioactivity obtained when a 100-fold
excess of unlabeled toxin was included. An acceptable level of nonspecific bind-
ing was 20% or less. Specific binding data were subjected to Scatchard analyses.
All radiolabeled DT binding assays were performed in duplicate, and at least two
assays were performed for each cell line. Each assay included the same positive
and negative control cell lines described above for the abbreviated cytotoxicity
assay.
Expression and purification of recombinant HB-EGF proteins. The recombi-
nant HB-EGF proteins [mature Mk HB-EGF, HB-EGF, HB-EGF(I117A/
L148A), and HB-EGF(Y138A/L148A)] were expressed from pET21a/WT,
pET21a/HB, pET21a/HB/I117A/L148A, and pET21a/HB/Y138A/L148A,
respectively, in E. coli BL21(DE3). All recombinant HB-EGF proteins contained
a T7 tag at their amino termini to facilitate the purification step. To prevent the
expression of the histidine tag at the carboxyl terminus of the proteins, which
might interfere with DT binding, a termination codon was introduced into the
plasmids before the histidine tag-coding region. The overexpressed recombinant
HB-EGF proteins formed inclusion bodies, which were isolated and dissolved in
8 M urea. The recombinant HB-EGF proteins were refolded by sequential
dialytic removal of urea in 25 mM Tris buffer with 4, 2, 1, and 0 M urea steps, in
the presence of reduced/oxidized glutathione (2.0/0.2 mM) (29). The refolded
recombinant HB-EGF proteins were concentrated and purified by T7 affinity
column as described in the manufacturer’s instructions.
Assay for 125I-DT binding inhibition. A LCD9/Mk HB-EGF cell line (n 
15,000) was used for this assay. LCD9/Mk HB-EGF cells are mouse LCD9 cells
that were obtained by transfection with pMkHB-EGF and stably express cell
surface DT receptor/Mk proHB-EGF (12).
Forty-eight-well plates were seeded at 4  104 LCD9/HB-EGF cells per well.
After 3 days of incubation at 37°C in 5% CO2, confluent monolayers were
washed twice with ice-cold phosphate-buffered saline (PBS) (8.8 mM Na2HPO4,
1.2 mM KH2PO4, 140 mM NaCl, 10 mM KCl, 0.5 mM MgCl2, and 1.0 mM CaCl2
[pH 7.4]), and then ice-cold binding medium (medium 199) (50-g ml1 bovine
serum albumin, 100-g ml1 gelatin, and 20 mM HEPES, pH 7.4) was added to
the monolayers and preincubated for 30 min at 4°C. The preincubation medium
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was removed, and the monolayers were again washed twice with ice-cold PBS.
The monolayers were incubated with the recombinant HB-EGF proteins in the
absence or in the presence of heparin (10 U/ml) for 5 h at 4°C. Binding medium
(in the absence or in the presence of heparin) containing 125I-DT (5 nM, initial
saturating concentration) and six various concentrations (0 to 450 nM) of re-
combinant HB-EGF proteins were incubated with the monolayer of LCD9/Mk
HB-EGF cells at 4°C for 5 h. Counts bound in the presence of competitor were
compared to those in the absence and reported as a percentage of the latter. In
the experiments shown, LCD9/Mk HB-EGF cells bound about 10,000 cpm in the
absence of competitor. All 125I-DT binding assays were performed in duplicate,
and at least two assays were performed for each cell line.
Assay for mitogenic activity. The BALB/c/3T3 cell line (ATCC CCL-163) was
used for this assay. Twenty-four-well plates were seeded at 105 BALB/c/3T3 cells
per well. After 3 days of incubation at 37°C in 5% CO2, about 95% confluent
monolayers were obtained and were washed once with PBS and once with assay
medium (1:1 Dulbecco’s minimal essential medium containing 1.5 g of NaCO3/
liter and Waymouth’s medium containing 1.5 g of NaCO3/liter, with 0.1% L-
glutamine and 1% insulin-transferrin-selenium-X). The cells were then incu-
bated for 24 h in the assay medium to serum starve the cells. Dead cells were
removed by washing once with PBS and once with assay medium. The various
concentrations of recombinant HB-EGF proteins in assay medium were added to
the monolayers and incubated at 37°C in 5% CO2 for 3 days. The cells were then
incubated with 5 Ci of [methyl-3H]thymidine/well for 3 h at 37°C in 5% CO2.
The radioactive media were aspirated, and the cells were detached with trypsin-
EDTA. The contents of the well plus 1 ml of PBS rinse were collected on a glass
fiber filter using vacuum manifolds (Hoefer Scientific Instruments). Three 1-ml
aliquots of PBS, three 1-ml aliquots of 10% trichloroacetic acid, and three 1-ml
aliquots of 95% ethanol, all chilled on ice, were passed through each filter. The
filters were dried, and the amount of radioactive thymidine incorporated into
DNA was determined by scintillation counting (2). All assays for mitogenic
activity were performed in duplicate, and at least two assays were performed for
each cell line.
Surface plasmon resonance. The BIAcore 2000 system with CM5 sensor chips
was employed as described previously (4) with modifications. The commercially
available mature Hu HB-EGF (as a positive control), the commercially available
mature Hu AR (as a negative control), and the recombinant HB-EGF proteins
expressed in E. coli and purified by T7 affinity column were immobilized using
the standard amine-coupling protocol provided by Pharmacia and using a flow
rate of 10 l/min. A running buffer (modified buffer of tissue culture medium 199
with Hanks salts containing CaCl2, KCl, KH2PO4, MgSO4, NaCl, NaH2PO4,
C2H3O2Na, NaHCO3, and Tween 80, pH 7.4) flow rate of 30 l/min was used in
the kinetic analysis experiments. The coupling of HB-EGF and AR proteins onto
the chips resulted in a range of 250 to 350 resonance units immobilized on the
sensor chips. A range of DT concentrations (20 nM to 1 M) was injected over
the CM5 chip with the immobilized HB-EGFs or AR. The injections were
performed at 25°C using the kinject method of injection. Injections of DT at
concentrations of 100 to 400 nM were used in the 1:1 analysis of the DT:HB-
EGF complex. A blank control used to monitor nonspecific binding to the sensor
chip surface was achieved by activating and inactivating the carboxymethylated
dextran in the first flow cell without coupling any ligand to this flow cell. No
binding was observed when running buffer alone (without DT) was passed over
the immobilized HB-EGF, indicating that none of the components in the running
buffer bound to HB-EGF (data not shown). Also, no binding was observed when
1 M DT was allowed to pass over immobilized AR as a negative control (data
not shown). Bulk refractive index shifts were removed from the analysis by
subtraction of the surface plasmon resonance response observed for running
buffer passed over the first flow cell from the binding curves observed for the
interaction of DT with HB-EGF. Version 3.0 of the BIAcore software package
was used to analyze these curves. The kinetic experiments were performed twice,
each time using a different chip.
RESULTS AND DISCUSSION
Recombinant mature Hu HB-EGF (residues 63 to 148 [Fig.
1A]) binds radiolabeled DT and therefore inhibits the binding
of radiolabeled DT to toxin receptor-bearing cells (26), sug-
gesting that mature HB-EGF could be used as an antidote for
diphtherial disease.
Inhibition of DT binding by mature HB-EGF in the absence
or presence of heparin. Preliminary experiments showed that
wild-type mature Mk HB-EGF and the commercially available
mature Hu HB-EGF inhibited the binding of 125I-DT to wild-
type receptor-bearing cells (LCD9/Mk HB-EGF); a detailed
analysis of the inhibition is shown in Fig. 2. Both proteins
showed the same pattern of DT binding inhibition, suggesting
that our purified recombinant mature Mk HB-EGF protein
refolded correctly. Lanzrein et al. (28) reported that radioio-
dinated DT-HB-EGF complexes can bind to cells via binding
of the HB domain to cell surface HSPGs. To confirm this
possibility, we performed the same experiment in the presence
of heparin which we expected would bind to the HB domain
and block the binding of the HB domain to cell surface
HSPGs. In the presence of heparin, there was a dramatic
decrease in the heparin-dependent binding of radioiodinated
DT to cells (Fig. 2). Therefore, to eliminate the HB effect, we
prepared a recombinant truncated HB-EGF protein (residues
106 to 149, HB-EGF) which lacks the amino terminus, in-
cluding most of the HB domain (i.e., lacks 93KRKKKGK and
103KKR but not 110RKYK [Fig. 1A]).
Inhibition of DT binding by truncated HB-EGF. Experi-
ments on the inhibition of radiolabeled DT binding were then
performed with the purified recombinant HB-EGF and ma-
ture Mk HB-EGF proteins in the absence or the presence of
heparin (Fig. 3). The recombinant HB-EGF protein at all
concentrations, in the absence of heparin, was a more effective
inhibitor of DT binding than was recombinant mature Mk
HB-EGF, and addition of heparin showed only a small effect
on toxin binding. Thus, HB-EGF appears to be a better
candidate for neutralizing DT than wild-type mature HB-EGF.
DT binding ability of cells expressing mutant DT receptors.
Since mature HB-EGF is a known ligand of the EGF receptor
and is thus highly mitogenic, the mitogenic (tumorigenic) effect
would need to be reduced to make the mature HB-EGF safe
for in vivo use. Accordingly, we first employed site-directed
FIG. 2. Radiolabeled DT binding inhibition by the recombinant
mature Hu and Mk HB-EGF proteins. The specific bound 125I-DT is
plotted against the concentration of competitors, the recombinant
mature Hu HB-EGF ({, }) or the recombinant mature Mk HB-EGF
(, ), in the absence ({, ) or the presence (}, ) of heparin (10
U/ml). The average from duplicate wells was calculated and plotted.
Results are representative of at least two separate experiments.
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mutagenesis to destroy the mitogenic activity of HB-EGF with-
out affecting its DT binding ability.
All members of the EGF protein family have an EGF-like
domain containing six conserved residues with a characteristic
pattern (CX7CX3-5CX10-12CXCX5GXRC) that form three di-
sulfide bonds (linked C1OC3, C2OC4, and C5OC6) (Fig.
1B). All growth factors of the EGF family bind to the EGF
receptor through their EGF-like domain, even though they
have quite a few nonconserved amino acids within this domain
(Fig. 1B). Using site-directed mutagenesis of EGF and TGF-,
a number of conserved amino acid residues have been shown
to be involved in activation of the EGF receptor. The positions
of these residues (using the numbering system based on the
HB-EGF precursor [Fig. 1A]) are 115, 117, 127, 138, 142, and
148 (Fig. 1B); the highly conserved leucine residue at position
148 has been shown to be the most critical residue involved in
the interaction with the EGF receptor (6).
The EGF-like domain of HB-EGF, unlike that of the other
EGF family members, has the unique capability of binding DT.
Our laboratory found that 3 residues in this domain, Ile133, His135,
and Glu141, play critical roles in DT binding; Leu127 may also
contribute to DT binding (10). Furthermore, the crystal structure
study of a complex of DT with part (residues 73 to 147) of the
extracellular domain of Hu HB-EGF, which includes the EGF-
like domain, demonstrated that these 4 amino acid residues, as
well as Arg142, are in close contact with the toxin (29). Based on
this rationale, we used site-directed mutagenesis to convert
Phe115, Ile117, Tyr138, and Leu148 to alanine, either alone or in
combination with L148A. We hoped to find mutations that affect
mitogenicity without affecting DT binding.
We first analyzed the DT binding ability of LCD9 cells stably
expressing mutant DT receptors to test whether any of the
mutations change the receptor’s DT binding ability. Table 1
summarizes the data for toxin receptor affinity and the number
of DT binding sites per cell for wild-type and seven different
mutant DT receptors. The DT receptor affinity was decreased
3-fold for the LCD9/HB-EGF(F115A) cell line (Kd  20.0
nM) and 2-fold for the LCD9/HB-EGF(F115A/L148A) cell
line (Kd  15.9 nM), compared to the cell line expressing the
wild-type DT receptor (Kd  7.0 nM). This result suggests that
Phe115 may also be involved in DT binding. Mitamura et al.
(33) had earlier reported that the DT binding activity of a
F115Y mutant was also moderately decreased.
The DT binding affinity was increased 2-fold for both the
LCD9/HB-EGF(I117A) cell line (Kd 4.0 nM) and the LCD9/
HB-EGF(I117A/L148A) cell line (Kd  3.0 nM). The DT
binding affinity was also increased 2-fold for the LCD9/HB-
EGF(L148A) cell line (Kd  3.6 nM). It is interesting that
these mutant DT receptors display a higher affinity for DT than
does the wild-type DT receptor. This increased affinity is prob-
ably a reflection of the decreased level of expression of cell
surface DT receptor/Mk proHB-EGF (Table 1) at a constant
level of expression of CD9, which we previously showed results
in a higher Mk CD9/Mk proHB-EGF ratio and in an increased
receptor affinity (12). The DT receptor affinities of the LCD9/
HB-EGF(Y138A) cell line (Kd  6.6 nM) and of the LCD9/
HB-EGF(Y138A/L148A) cell line (Kd 6.8 nM) are similar to
that of the wild-type DT receptor. In summary, these results
suggest that residues Ile117, Tyr138, and Leu148 are not involved
in DT binding but that residue Phe115 is. Therefore, residues
Ile117, Tyr138, and Leu148 are good candidates to mutate in
order to attempt to reduce the tumorigenic effect without af-
fecting the toxin binding ability. Furthermore, the double mu-
tants I117A/L148A and Y138A/L148A, which have a mutation
in the most critical residue (Leu148), might be even better
candidates. Thus, the double mutants I117A/L148A and
Y138A/L148A were created in the truncated HB-EGF back-
ground, resulting in HB-EGF(I117A/L148A) and HB-
EGF(Y138A/L148A) proteins. These proteins were then
tested for their mitogenic activity and their ability to inhibit
binding of radiolabeled DT to cells.
HB-EGF(I117A/L148A) displays a lower mitogenic activ-
ity. The mitogenic activity of the commercial Hu HB-EGF, the
purified Mk HB-EGF, HB-EGF, HB-EGF(I117A/L148A),
and HB-EGF(Y138A/L148A) proteins was examined using se-
rum-starved BALB/c/3T3 cells (Fig. 4). As expected, the recom-
binant mature Hu HB-EGF and the purified recombinant Mk
FIG. 3. Radiolabeled DT binding inhibition by the recombinant trun-
cated HB-EGF and mature HB-EGF proteins. The specific bound
125I-DT is plotted against the concentration of competitors, the recombi-
nant mature Mk HB-EGF (, ) or the recombinant truncated HB-
EGF (‚, Œ), in the absence (, ‚) or the presence (, Œ) of heparin (10
U/ml). The average from duplicate wells was calculated and plotted.
Results are representative of at least two separate experiments.
TABLE 1. Summary of DT binding affinity and the number of DT
binding sites per cell
Cell linea Kd (nM)b n (105)b
LCD9/Mk HB-EGF 7.0 8.7
LCD9/F115A 20.0 5.4
LCD9/I117A 4.0 1.7
LCD9/Y138A 6.6 6.5
LCD9/L148A 3.6 2.4
LCD9/F115A/L148A 15.9 5
LCD9/I117A/L148A 3 4.6
LCD9/Y138A/L148A 6.8 11.8
a These cell lines are LCD9 cells expressing wild-type or mutant Mk proHB-
EGF/DT receptors.
b All binding assays were done in duplicate and were performed at least twice
for each cell line with the average calculated Kd and number of binding sites per
cell (n) being reported.
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HB-EGF showed similar, high levels of mitogenicity. Interest-
ingly, HB-EGF showed a similar mitogenic effect to that of the
wild-type proteins, a result consistent with the fact that the EGF-
like domain is the one that interacts with the EGF receptor.
Surprisingly, the mitogenic effect of HB-EGF(Y138A/
L148A) was not decreased but was similar to that of the com-
mercial Hu HB-EGF, the purified Mk HB-EGF, and HB-
EGF, although the two mutations in this truncated protein are
in highly conserved residues in the EGF family which have
been shown, in EGF and TGF-, to be involved in binding to
the EGF receptor (Fig. 1B).
More important was the mitogenic effect observed with
HB-EGF(I117A/L148A); it was decreased at least 100-fold
when the 50% effective dose (ED50) of HB-EGF(I117A/
L148A) (ED50 	 10 nM) was compared with those of mature
Hu HB-EGF, Mk HB-EGF, HB-EGF, and HB-EGF
(Y138A/L148A) (ED50	0.06 to 0.1 nM). The extremely low
mitogenic activity suggested that HB-EGF(I117A/L148A)
would be the best candidate for an antidote against diphtherial
disease.
HB-EGF(I117A/L148A) inhibits binding of DT as well as
HB-EGF. The experiment for inhibition of radiolabeled DT
binding was performed with HB-EGF(I117A/L148A) and
with HB-EGF proteins; they both showed a similar pattern of
inhibition of DT binding (Fig. 5).
High DT binding affinity of HB-EGF(I117A/L148A). We
examined the binding of the recombinant HB-EGF, HB-EGF,
and HB-EGF(I117A/L148A) to DT, employing surface plas-
mon resonance. Table 2 summarizes the data for the association
rate constant (Ka), the dissociation rate constant (Kd), and the
apparent dissociation constant (KD) of the recombinant HB-EGF
proteins towards DT. Our purified recombinant wild-type Mk
HB-EGF (KD  3.4  10
8 M) showed an apparent KD very
similar to that of the commercial recombinant Hu HB-EGF (KD
 3.8 108 M); these apparent KD values obtained here are in
agreement with those previously reported (4). Interestingly, the
apparent KD for HB-EGF (KD  5.2  10
8M) was similar to
that of the recombinant Hu HB-EGF and of the purified recom-
binant Mk HB-EGF, in agreement with the DT binding inhibition
results described above. High-affinity binding of HB-
EGF(I117A/L148A) for DT was also observed (KD  10 10
8
M); however, it was2-fold lower than that obtained with HB-
EGF.
In this study we demonstrated that the truncated mutant
protein HB-EGF(I117A/L148A) resulted in a DT receptor
analog that both strongly inhibited binding of radioiodinated
DT to cells and displayed a 100-fold-lower mitogenic effect.
Therefore, we conclude that the HB-EGF(I117A/L148A)
protein may be a suitable candidate for a diphtheria antidote.
This protein will now be tested in vivo employing a toxin-
sensitive animal model. We propose to start by testing that
concentration of HB-EGF(I117A/L148A) that inhibits bind-
ing of radioiodinated DT by 50%, 10 nM (Fig. 5), a concen-
FIG. 4. Induction of DNA synthesis in BALB/c/3T3 cells by the
recombinant mature Hu HB-EGF, mature Mk HB-EGF, HB-EGF,
HB-EGF(I117A/L148A), and HB-EGF(Y138A/L148A) proteins.
The serum-starved BALB/c/3T3 cells were stimulated with various
concentrations of recombinant mature Hu HB-EGF ({), mature Mk
HB-EGF (), HB-EGF (‚), HB-EGF(I117A/L148A) (E), or
HB-EGF(Y138A/L148A) (ƒ) for 3 days, and the amount of [3H]thy-
midine incorporation was measured as described in Materials and
Methods. The average from duplicate wells was calculated and plotted.
Results are representative of at least two separate experiments.
FIG. 5. Radiolabeled DT binding inhibition by the truncated HB-
EGF(I117A/L148A) and the truncated HB-EGF proteins. The spe-
cific bound 125DT is plotted against the concentrations of competitors,
the recombinant truncated HB-EGF (‚) and the recombinant trun-
cated mutant HB-EGF(I117A/L148A) (E), used in the assay. The
average from duplicate wells was calculated and plotted. Results are
representative of at least two separate experiments.
TABLE 2. Interaction of DT with immobilized HB-EGF
moleculesa
Recombinant HB-EGF
protein used
Avg Ka (104)
(1/Ms)
Avg Kd (103)
(1/S)
Avg KD (108)
(M)
Mature Hu HB-EGF 4.6 1.8 3.8
Mature Mk HB-EGF 6.4 2.2 3.4
HB-EGF 4.9 2.5 5.2
HB-EGF(I117A/L148A) 7.1 7.1 10
a The BIAcore 2000 system with CM5 sensor chips was employed. The recom-
binant HB-EGF proteins were immobilized on CM5 sensor chips by standard
amine coupling, and the kinetic experiments were performed as described in
Materials and Methods. This table shows values for a representative experiment
of two separate experiments.
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tration which is expected to result in about a 50%-lower mi-
togenic effect than that obtained with the truncated and
mature HB-EGF molecules (Fig. 4).
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